Sexual Health Buzz

The FDA has approved Teva Pharmaceutical Industries’ ANDA to market famciclovir 125, 250, and 500 mg tablets, indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompromised patients, recurrent mucocutaneous herpes simplex infections in HIV-infected patients, acute herpes zoster (shingles), and the treatment or suppression of recurrent genital herpes in immunocompetent patients. The medication is generically equivalent to Famvir by Novartis. Teva has been awarded a 180-day period of marketing exclusivity.

Read what people have to say about Famvir

Talk about Famvir and other Herpes Antivirals